Company intelligence / Profile preview

Orfonyx Bio

Oxford, England, United Kingdomorfonyx.com ↗

Ownership: Private
Employees: ~8
Development stage: Preclinical

Overview

Orfonyx Bio is a seed-stage biotech company developing a proprietary platform, APEX, for upregulating protein expression via antisense oligonucleotides that target repressive motifs in gene UTRs. The company is advancing towards nominating its first drug candidate and entering IND-enabling studies. No clinical results have been reported yet; the focus remains on R&D and platform development.

Therapeutic areas: Rare Diseases
Modalities: Antisense oligonucleotides (ASOs)Genetic medicines targeting regulatory elements in untranslated regions of genes
Industry: Biotech

Beyond the preview

Go deeper on Orfonyx Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orfonyx Bio.

Explore the full profile